Imexhs Ltd · ASX:IME
Imexhs — Investor Presentation (February 2026)
25 slides from Imexhs's investor presentation, Feb 27, 2026
Slide 1: FY25 Results
FY25 Results 27 February 2026
Slide 2: One Company with two businesses democratizing access to medical imaging expertise
02 One Company with two businesses aimed at democratizing access to medical imaging expertise Software Business Radiology Services Medical imaging software (RIS, Radiology services, primarily PACS, universal viewer, AI) in Colombia
Slide 3: Operational Performance
03 Operational Performance Key indicators of growth, platform reliability, and patient engagement over the past eight quarters. Installed Sites Key Platform Metrics 564 8.3M 556 Studies Reported 549 3.6M 546 Portal Users 525 521 Active patients with digital access 518 8.2M 511 Portal Sessions 2.3x a
Slide 4: FY25 Results at the top end of Guidance
04 FY25 Results at the top end of Guidance ➢ Revenue of $29.0m up from $26.5m or 10% vs pcp and ahead of revenue guidance provided of $27.5m–$28.2m and; ➢ Underlying EBITDA of $1.6m up vs $0.5m in pcp and at the top end of guidance of $1.3m–$1.6m.
Slide 5: FY25 Financial Highlights
05 FY25 Financial Highlights Revenue Annual Recurring Underlying Revenue (ARR) EBITDA2 Up 10% yoy Up 16% yoy Up 6% on a constant $29.0m Up 7% on a constant $34.8m Up vs $0.5m in pcp $1.6m currency basis1 currency basis H2 EBITDA Cash Debt Up vs $0.3m in H1 FY25 $1.3m vs $2.1m at $3.3m vs $1.2m at $0
Slide 6: FY25 Business Unit Results
06 FY25 Business Unit Results ➢ Software primarily relates to sales of IMEXHS $M Software Radiology Corporate Total Enterprise and growing IMEXHS Cloud business ➢ Revenue up 12% vs pcp | ARR up 19% vs pcp Revenue 10.0 19.03 - 29.0 ➢ Underlying EBITDA $3.0m (30% margin) vs $3.2m (36% margin) in pcp U
Slide 7: Progress in ARR
07 Progress in ARR ARR at 31 Dec-25 • $34.8m, up 16% vs pcp: ➢ $11.8m from Software, up 19% vs pcp ($9.9m); and ➢ $23.0m from Radiology services, up 14% vs pcp ($20.1m) (1) Constant currency basis assumes that historical results at each year end are converted at the 31 Dec-25 exchange rate. This rem
Slide 8: Financial turning point: positive EBITDA, stronger cash collection, lower debt
Financial turning point: positive EBITDA, 08 stronger cash collection, lower debt What we did What it delivered • Tightened credit terms and collections • Revenue: $29.0m, up 10% vs pcp. discipline; focused on on-time payors. • Underlying EBITDA: H2 $1.3m vs H1 • Cost program in motion (AI agents- $
Slide 9: Our focus right now
ime xHS Our focus right now
Slide 10: Aquila+ AI agents ready; partners scaling; pipeline strengthening
10 Aquila+ AI agents ready; partners scaling; pipeline strengthening • Product-ready for scale: Aquila+ live across teleradiology, clinics and hospital groups (agents driving efficiency and quality , one-click tenant activation, 99.9% uptime). • Go-to-market discipline: strengthened partner channel,
Slide 11: Aquila+: agentic AI platform that lowers total cost-to-serve
11 Aquila+ : agentic AI platform that lowers total cost-to-serve → New agentic approach to critical → Faster from scan to → ~70% lower marginal points of the workflow. the answer: shorter report cost-to-serve per new turn around and SaaS tenant; 1-click tenant → ~40% faster worklists; fewer clicks p
Slide 12: Expand margins through pricing discipline, automation and mix
12 Expand margins through pricing discipline, automation and mix Pricing & Terms Automatization & Portfolio Discipline Unit Cost & Mix → Apply improved terms & → AI-orchestrated → Prioritize higher-margin conditions and workflows (already software modules and segmentation. reducing service costs). e
Slide 13: Collections up, cash stable, debt down - discipline sustained
13 Collections up, cash stable, debt down - discipline sustained Operating Discipline Outcomes • Enhanced credit controls, proactive • Net Operating cash inflow of $0.6m, up collections, and structured repayment from cash outflow of ($0.6m) in pcp. arrangements where appropriate. • Debt reduced to $
Slide 14: Software Business Highlights - IMEXHS
14 Software Business Highlights - IMEXHS ➢ Pipeline strengthened after enhanced inbound/outbound marketing strategy. ➢ Key wins/renewals: • Salud Total Group (Colombia): 2 enterprise renewals expanding value via cloud migration + broader functionality + additional services ($348k NARR aggregate). •
Slide 15: Radiology Services - RIMAB
15 Radiology Services - RIMAB ➢ Opportunistic growth strategy, larger, strong margin, credit worthy clients. ➢ New contract: Oncolife (Colombia) high-complexity services, grew from ARR expected of ~$1.4m, to $2.1m actuals. This contract includes services + software, supported by IMEXHS Enterprise RI
Slide 16: FY25 Financials
iIMexXHS FY25 Financials
Slide 17: Income Statement
17 Income Statement $’000 FY25 FY24 Var Revenue 28,970 26,450 2,520 Other revenue 25 120 (95) ➢ FY25 revenue of $29.0m, up 10% vs pcp and up 6% on a constant Total revenue 28,995 26,569 2,426 currency basis(1). Expenses (32,034) (29,137) (2,897) ➢ FY25 Underlying EBITDA(2) of $1.6m vs $0.5m in pcp.
Slide 18: Balance Sheet
18 Balance Sheet $’000 Dec-25 Dec-24 Cash 3,299 2,072 Trade & other receivables 9,993 6,856 ➢ Closing cash balance of $3.3m at 31 Inventories 146 328 Dec-25, up from $2.1m in pcp. Current assets 13,438 9,256 Trade & other receivables 531 1,149 ➢ Net Assets of $15.9m. PPE 3,106 3,274 ➢ Intangible ass
Slide 19: Summary Cash Flow
19 Summary Cash Flow $'000 FY25 FY24 Net cash (used in)/from operating activities 565 (635) ➢ Closing cash balance of $3.3m vs $2.1m in pcp. Net cash (used in)/from investing activities (1,193) (766) ➢ Net cash from operating activities was Net cash (used in)/from financing activities 1,678 1,181 $0
Slide 20: Outlook & Priorities FY26
20 Outlook & Priorities FY26 ➢ Scale Software: Accelerated software growth, with multi-front improvements and efficiencies, to be the preferred product for Radiologists across the region. ➢ Pipeline & GTM: Pipeline strengthened with new marketing strategy; partner channel increasing contribution to
Slide 21: FY26 Guidance
21 FY26 Guidance ➢ The company expects to; o exceed FY25 Underlying EBITDA, o be cash positive for FY26, o grow software revenue at a faster rate than in FY25, and o see more of the growth in Revenue, Earnings and Cash in H2. ➢ The company expects to provide more specific guidance at the first half
Slide 22: THANK YOU
THANK YOU
Slide 23: Q&A
Q&A
Slide 24: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 25: FY25 Results
FY25 Results 27 February 2025